Novo Nordisk A/S & Anr v. Dr. Reddy's Laboratories Limited

When a patented drug becomes a household name and a global revenue engine, generic manufacturers inevitably circle like sharks. The collision between an originator's hard-won patent rights and a competitor's push for market entry is one of the most consequential battles in the pharmaceutical world. This case captures that exact moment of collision, where billions in potential revenue hang on the court's next move.

Novo Nordisk A/S, the originator behind the blockbuster semaglutide composition, found itself facing an unwelcome entrant: Dr. Reddy's Laboratories Limited, one of India's largest generic pharmaceutical manufacturers. Concerned about the launch of a competing product that allegedly infringed its patented composition involving semaglutide, Novo Nordisk moved quickly and filed a commercial suit. The core of the dispute centered on the patented semaglutide composition, with Novo Nordisk seeking urgent judicial intervention to halt what it viewed as unauthorized commercialization of its protected innovation.

Novo Nordisk came to court seeking an interim injunction, a powerful pre-trial remedy that could freeze Dr. Reddy's activities before the full case was even heard. The company argued that its patented semaglutide composition was being infringed, and that without immediate court intervention, it would suffer irreparable harm. Dr. Reddy's Laboratories, on the other hand, contested these claims, putting forward its own position through affidavits. Both sides presented their competing narratives through sworn statements, setting up a classic pharmaceutical patent friction: the originator's claim to exclusive commercial rights versus the generic manufacturer's push for market access.

Rather than delivering an immediate ruling on the injunction request, the court took a measured procedural approach. It noted the affidavits filed by both parties, acknowledged the procedural applications made before it, and directed the parties to proceed with their pleadings. In other words, the court chose to let the formal litigation machinery run its course before deciding on the critical interim relief. The outcome of the dispute remains pending, with the next phase of the case hinging on the completion of pleadings and further hearings.

For founders and IP professionals in the pharmaceutical and biotech space, this case is a reminder that patent enforcement is rarely a single courtroom moment; it is a process. Securing a patent is only half the battle; the other half is being prepared to litigate swiftly, file comprehensive affidavits, and navigate procedural requirements when a competitor enters the market. Companies holding valuable composition patents should have pre-drafted enforcement strategies, including ready-to-file injunction applications and well-organized technical evidence, so that when a generic challenger appears, they can move with the speed and precision that interim injunction proceedings demand.